Il

HIMSS21 Brings Changemakers Together

Retrieved on: 
Wednesday, July 28, 2021
Healthcare Information and Management Systems Society, Consumer Electronics Show, Las Vegas, United States responses to the COVID-19 pandemic, States of the United States, United States

HIMSS21 is both a digital and in-person experience in Las Vegas, Nevada, from Aug. 9-13, so everyone, everywhere can join together to Be the Change.

Key Points: 
  • HIMSS21 is both a digital and in-person experience in Las Vegas, Nevada, from Aug. 9-13, so everyone, everywhere can join together to Be the Change.
  • To align with this guidance, Proof of Vaccination and masks are required for all attendees, exhibitors and HIMSS staff on the HIMSS21 Campus and in all public spaces.
  • The following protocols will also be in place during HIMSS21:
    All primary venues within the HIMSS21 campus utilize hospital-grade (or better) air ventilation systems.
  • PPE will be available throughout the HIMSS21 Campus.

Timberline Knolls Offers Advice for Coping with Eating Disorder Symptoms During Summer

Retrieved on: 
Wednesday, July 28, 2021
Abnormal psychology, Psychiatry, Eating disorders, Psychology, Psychiatric diagnosis, Mind, Behavioral neuroscience, Binge eating disorder, Emotional eating

However, for those struggling with an eating disorder , the summer months can present new challenges in managing symptoms and maintaining recovery.

Key Points: 
  • However, for those struggling with an eating disorder , the summer months can present new challenges in managing symptoms and maintaining recovery.
  • Body image concerns are one of the main reasons why summer may be a difficult time for individuals in eating disorder recovery.
  • Here are some tips for coping with eating disorder symptoms during the summer:
    The summer can be a difficult time for those in eating disorder recovery.
  • We are also on Facebook Timberline Knolls , LinkedIn Timberline Knolls and Twitter @TimberlineToday.

Ohio Enacts Nurse Licensure Compact (NLC)

Retrieved on: 
Wednesday, July 28, 2021
Regions of the United States, Ohio, States of the United States, Mike DeWine, DeWine, Nurse Licensure Compact

Mike DeWine signed the NLC into law in the state of Ohio on July 1, 2021.

Key Points: 
  • Mike DeWine signed the NLC into law in the state of Ohio on July 1, 2021.
  • Ohio is the 38th jurisdiction to have enacted the NLC.
  • With the governor's signature, nurses can have confidence that there is opportunity in Ohio that they may not be able to find in other states."
  • Starting on this date, Ohio residents will be able to apply for a multistate license and nurses residing in other states who hold a multistate license will be able to begin practicing in Ohio.

New ACGME Equity Matters Initiative Aims to Increase Diversity, Equity, and Inclusion within Graduate Medical Education and Promote Health Equity

Retrieved on: 
Wednesday, July 28, 2021
Medical education in the United States, Health, Articles, Accreditation Council for Graduate Medical Education, Residency, Health equity, Medical education, Draft:Dotun Ogunyemi

The initiative aims to drive change within graduate medical education (GME) by increasing physician workforce diversity and building safe and inclusive learning environments, while promoting health equity by addressing racial disparities in health care and overall population health.

Key Points: 
  • The initiative aims to drive change within graduate medical education (GME) by increasing physician workforce diversity and building safe and inclusive learning environments, while promoting health equity by addressing racial disparities in health care and overall population health.
  • ACGME Equity Matters launched last week with the convening of the first Learning Community to embark on the 18-month engagement cycle.
  • The ACGME Equity Matters program seeks to promote the necessary infrastructure in learning that will promote change in graduate medical education practices, said William A. McDade, MD, PhD, chief diversity, equity, and inclusion officer, ACGME.
  • The ACGME's mission is to improve health care and population health by assessing and enhancing the quality of resident and fellow physicians' education through advancements in accreditation and education.

Pactiv Evergreen to Exit Coated Groundwood Paper Business Following Years of Market Decline

Retrieved on: 
Wednesday, July 28, 2021
Pactiv, Companies, Pine Bluff, Arkansas, Lake Forest, Illinois

Pactiv Evergreen will exit the coated groundwood paper business in Q4-2021.

Key Points: 
  • Pactiv Evergreen will exit the coated groundwood paper business in Q4-2021.
  • As a result, Pactiv Evergreen will permanently cease production of coated groundwood paper at its Pine Bluff, AR location by October 31, 2021.
  • LAKE FOREST, Ill., July 28, 2021 (GLOBE NEWSWIRE) -- Pactiv Evergreen today announced that the Company has made the difficult decision to exit the coated groundwood paper business.
  • As a result, the Company will permanently cease production of coated groundwood paper at its Pine Bluff, AR location.

Whole Earth Brands, Inc. to Participate in the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Wednesday, July 28, 2021
Sugar substitutes, Swerve, Canaccord Genuity, Genuity, Food, Sugar substitute, Canderel, Equal, Companies, Merisant

CHICAGO, July 28, 2021 (GLOBE NEWSWIRE) -- Whole Earth Brands, Inc. (the Company) (Nasdaq: FREE), today announced that Chief Executive Office Albert Manzone and Chief Financial Officer Andy Rusie will host a presentation at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11th at 4:00 PM ET.

Key Points: 
  • CHICAGO, July 28, 2021 (GLOBE NEWSWIRE) -- Whole Earth Brands, Inc. (the Company) (Nasdaq: FREE), today announced that Chief Executive Office Albert Manzone and Chief Financial Officer Andy Rusie will host a presentation at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11th at 4:00 PM ET.
  • Whole Earth Brands is a global food company enabling healthier lifestyles and providing access to premium plant-based sweeteners, flavor enhancers and other foods through our diverse portfolio of trusted brands and delicious products, including Whole Earth Sweetener, Wholesome, Swerve, Pure Via, Equal and Canderel.
  • With food playing a central role in peoples health and wellness, Whole Earth Brands innovative product pipeline addresses the growing consumer demand for more dietary options, baking ingredients and taste profiles.
  • We are committed to helping people enjoy lifes everyday moments and the celebrations that bring us together.

Option Care Health Appoints Dr. Seema Kumbhat to the Position of Chief Medical Officer

Retrieved on: 
Wednesday, July 28, 2021
Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, Germany, Industry economics), Companies

BANNOCKBURN, Ill., July 28, 2021 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the Company or Option Care Health)(Nasdaq: OPCH), the nations largest independent provider of home and alternate site infusion services, announced today that Dr. Seema Kumbhat has joined the Company as Chief Medical Officer.

Key Points: 
  • BANNOCKBURN, Ill., July 28, 2021 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the Company or Option Care Health)(Nasdaq: OPCH), the nations largest independent provider of home and alternate site infusion services, announced today that Dr. Seema Kumbhat has joined the Company as Chief Medical Officer.
  • Prior to joining Option Care Health, Dr. Kumbhat served as Senior Vice President and Regional Medical Officer for Fresenius Kabi.
  • As a physician, she brings a wealth of knowledge to the Option Care Health team, and Im confident she will make a positive impact in continuing efforts to elevate patient care, John Rademacher, Chief Executive Officer, commented.
  • Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates.

BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, TMS

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study

Retrieved on: 
Wednesday, July 28, 2021
Design of experiments, Clinical trials, Health sciences, Science, Health, Clinical research, Medical statistics, Drugs, Clinical study design, Adaptive design, Placebo-controlled study, COVID-19 vaccine

YAVNE, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced a positive outcome from a planned interim sample size re-estimation of its ongoing EscharEx® U.S. phase 2 adaptive design study for the treatment of venous leg ulcers (VLUs), designed to assess the safety and efficacy of EscharEx compared to gel vehicle (placebo control) and non-surgical standard-of-care (either enzymatic or autolytic debridement).

Key Points: 
  • "We are very pleased with the IDMC's recommendation to continue the EscharEx study as originally planned without modifying the study sample size, said Sharon Malka, Chief Executive Officer of MediWound.
  • The multicenter, prospective, randomized, placebo-controlled, adaptive design study, evaluating the safety and efficacy of EscharEx in debridement of VLUs.
  • The study includes a pre-defined interim assessment for futility and potential sample size adjustment.
  • EscharEx is an investigational product, currently under a U.S. phase 2 adaptive design study.

PolyPid to Report Second Quarter 2021 Financial Results and Operational Highlights on August 11, 2021

Retrieved on: 
Wednesday, July 28, 2021
Health sciences, Health, Life sciences, Communication, Forward-looking statement, Clinical trial, Surgery, Preventive healthcare

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics.

Key Points: 
  • PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics.
  • PolyPids lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).
  • This press release contains projections and other forward-looking statements regarding future events or our future financial performance.
  • Actual events or results may differ materially from those contained in the projections or forward-looking statements.